Rafael Fonseca: Higher rate of neuropathy for bortezomib vs carfilzomib
Rafael Fonseca, Hematologist at Mayo Clinic, shared a post on X:
“Much higher rate of serious neuropathy for bortezomib vs carfilzomib. Most trials on left used biweekly but two, marked by asterisk, use weekly.
This plots only Gr3/4 (available trial data) but grade 2 is important, and even grade 1.”
Dr. Rafael Fonseca, M.D., is a hematologist at Mayo Clinic, specializing in multiple myeloma and related conditions.. Dr. Fonseca’s expertise extends to diagnosing and treating plasma cell disorders, leading clinical trials that have advanced myeloma treatment. He has led research on genetic markers in myeloma. Dr. Fonseca has received numerous awards and honors, including the Damon Runyon-Walter Winchell Clinical Investigator Award and the International Waldenström Macroglobulinemia Research Award.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023